Background: A high expression of prostaglandin E2 (PGE2) is found in colorectal cancer. Therefore, blocking of PGE2 generation has been identified as a promising approach for anticancer therapy. Sulforaphane (SFN), an isothiocyanate derived from glucosinolate, is used as the antioxidant and anticancer agents. Methods: HT-29 cells were treated with various concentrations of SFN and compared to untreated cells for the expression of microsomal prostaglandin E synthase-1 (mPGES-1), cyclooxygenase 2 (COX-2), hypoxia-inducible factor-1 (HIF-1), C-X-C chemokine receptor type 4 (CXCR4), vascular endothelial growth factor (VEGF), and matrix metalloproteinase (MMP)-2 and MMP-9 at the mRNA level. The PGE2 level was measured by ELISA assay. Apoptosis was evaluated by the proportion of sub-G1 cells. The activity of caspase-3 was determined using an enzymatic assay. HT-29 cell migration was assessed using a scratch test. Results: SFN preconditioning decreased the expression of COX-2, mPGES-1, HIF-1, VEGF, CXCR4, MMP-2, and MMP-9. An apoptotic effect of SFN was preceded by the activation of caspase-3 as well as accumulation of cells in the sub-G1 phase of the cell cycle. SFN decreased PGE2 generation and inhibited the in vitro motility/wound-healing activity of HT-29 cells. Conclusions: SFN anticancer effects are associated with antiproliferative, antiangiogenic, and antimetastatic activities arising from the downregulation of the COX-2/ mPGES-1 axis.

1.
Bernards, R. (2003) Cancer: cues for migration. Nature 425: 247–248.
2.
Buchanan, F.G., D. Wang, F. Bargiacchi, R.N. DuBois (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451–35457.
3.
Chan, A.T., S. Ogino, C.S. Fuchs (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl J Med 356: 2131–2142.
4.
Dashwood, R.H., E. Ho (2008) Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutr Rev 66(suppl 1): S36–S38.
5.
Ettarh, R., A. Cullen, A. Calamai (2010) NSAIDs and cell proliferation in colorectal cancer. Pharmaceuticals 3: 2007–2021.
6.
Fimognari, C., P. Hrelia (2007) Sulforaphane as a promising molecule for fighting cancer. Mutat Res 635: 90–104.
7.
Fimognari, C., M. Nüsse, R. Cesari, R. Iori, G. Cantelli-Forti, P. Hrelia (2002) Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23: 581–586.
8.
Fujimoto, Y., S. Sakuma, C. Maruyama, T. Kohda (2014) Curcumin inhibits the proliferation of a human colorectal cancer cell line Caco-2 partially by both apoptosis and G2/M cell cycle arrest. Int J Pharmacol Res 4: 84–90.
9.
Fukuda, R., B. Kelly, G.L. Semenza (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63: 2330–2334.
10.
Gamet-Payrastre, L., P. Li, S. Lumeau, G. Cassar, M.-A. Dupont, S. Chevolleau, N. Gasc, J. Tulliez, F. Tercé (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60: 1426–1433.
11.
Haggar, F.A., R.P. Boushey (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191.
12.
Hara, S. (2017) Prostaglandin terminal synthases as novel therapeutic targets. Proc Jpn Acad Ser B Phys Biol Sci 93: 703–723.
13.
Ho, E., J.D. Clarke, R.H. Dashwood (2009) Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 139: 2393–2396.
14.
Jänne, P.A., R.J. Mayer (2000) Chemoprevention of colorectal cancer. New Engl J Med 342: 1960–1968.
15.
Johnson, J.J., H. Mukhtar (2007) Curcumin for chemoprevention of colon cancer. Cancer Lett 255: 170–181.
16.
Kamiyama, M., A. Pozzi, L. Yang, L. DeBusk, R. Breyer, P. Lin (2006) EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25: 7019–7028.
17.
Karimi Dermani, F., M. Saidijam, R. Amini, A. Mahdavinezhad, K. Heydari, R. Najafi (2017) Resveratrol inhibits proliferation, invasion, and epithelial-mesenchymal transition by increasing miR-200c expression in HCT-116 colorectal cancer cells. J Cell Biochem 118: 1547–1555.
18.
Kaur, J., S.N. Sanyal (2010) PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol 31: 623–631.
19.
Krishnamachary, B., S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G. Ferreira, N. Iyer, J. La-Rusch, B. Pak, P. Taghavi (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138–1143.
20.
Kunnumakkara, A.B., P. Diagaradjane, P. Anand, H.B. Kuzhuvelil, A. Deorukhkar, J. Gelovani, S. Guha, S. Krishnan, B.B. Aggarwal (2009) Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125: 2187–2197.
21.
Kurtova, A.V., J. Xiao, Q. Mo, S. Pazhanisamy, R. Krasnow, S.P. Lerner, F. Chen, T.T. Roh, E. Lay, P.L. Ho (2015) Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517: 209–213.
22.
Labianca, R., B. Nordlinger, G. Beretta, S. Mosconi, M. Mandala, A. Cervantes, D. Arnold; ESMO Guidelines Working Group (2013) Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6): vi64–vi72.
23.
Larsson, K., A. Kock, H. Idborg, M.A. Henriksson, T. Martinsson, J.I. Johnsen, M. Korotkova, P. Kogner, P.-J. Jakobsson (2015) COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci USA 112: 8070–8075.
24.
Livak, K.J., T.D. Schmittgen (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25: 402–408.
25.
Lu, D., C. Han, T. Wu (2011) Microsomal prostaglandin E synthase-1 (mPGES-1) promotes human cholangiocarcinogenesis through inhibition of PTEN pathway. FASEB J 25(suppl 1): 115–118.
26.
Manzano, A., P. Pérez-Segura (2012) Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? Sci World J 2012: 327341.
27.
Morgan, G. (2003) Can prostaglandin E2 be considered as involved in degeneration of Barrett’s and colonic mucosa? In Giuli, R. (ed): Barrett’s Esophagus: Columnar Lined Esophagus: 250 Questions, 250 Answers. Paris, John Libbey Eurotext, vol. 1, p. 646.
28.
Nakanishi, M., V. Gokhale, E.J. Meuillet, D.W. Rosenberg (2010) mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators”. Biochimie 92: 660–664.
29.
O’Callaghan, G., A. Houston (2015) Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 172: 5239–5250.
30.
Obermajer, N., R. Muthuswamy, K. Odunsi, R.P. Edwards, P. Kalinski (2011) PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71: 7463–7470.
31.
Pledgie-Tracy, A., M.D. Sobolewski, N.E. Davidson (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6: 1013–1021.
32.
Ranjbarnejad, T., M. Saidijam, S. Moradkhani, R. Najafi (2017a) Methanolic extract of Boswellia serrata exhibits anti-cancer activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Prostaglandins Other Lipid Mediat 131: 1–8.
33.
Ranjbarnejad, T., M. Saidijam, M.S. Tafakh, M. Pourjafar, F. Talebzadeh, R. Najafi (2017b) Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Hum Exp Toxicol 36: 692–700.
34.
Saltz, L.B. (ed.) (2007) Colorectal Cancer: Evidence-Based Chemotherapy Strategies. Toto-wa, Humana Press.
35.
Schneider, A., Y. Zhang, M. Zhang, W.J. Lu, R. Rao, X. Fan, R. Redha, L. Davis, R.M. Breyer, R. Harris (2004) Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 65: 1205–1213.
36.
Shan, Y., K. Wu, W. Wang, S. Wang, N. Lin, R. Zhao, A. Cassidy, Y. Bao (2009) Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-κB-DNA-binding activity in human bladder T24 cells. Int J Oncol 34: 1129–1134.
37.
Shan, Y., L. Zhang, Y. Bao, B. Li, C. He, M. Gao, X. Feng, W. Xu, X. Zhang, S. Wang (2013) Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 24: 1062–1069.
38.
Shankar, S., S. Ganapathy, R.K. Srivastava (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 14: 6855–6866.
39.
Singh, A.V., D. Xiao, K.L. Lew, R. Dhir, S.V. Singh (2004) Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83–90.
40.
Teixeira, M.C., M.I. Braghiroli, J. Sabbaga, P.M. Hoff (2014) Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol 20: 15060.
41.
van Rees, B.P., A. Sivula, S. Thorén, H. Yokozaki, P.J. Jakobsson, G.J.A. Offerhaus, A. Ristimäki (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107: 551–556.
42.
Wang, D., R.N. DuBois (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781–788.
43.
Watanabe, K., T. Kawamori, S. Nakatsugi, K. Wakabayashi (2000) COX-2 and iNOS, good targets for chemoprevention of colon cancer. Biofactors 12: 129–133.
44.
Woo, K.J., T.K. Kwon (2007) Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter. Int Immunopharmacol 7: 1776–1783.
45.
Wu, C.-Y., C.-J. Wang, C.-C. Tseng, H.-P. Chen, M.-S. Wu, J.-T. Lin, H. Inoue, G.-H. Chen (2005) Helicobacter pylori promote gastric cancer cells invasion through a NF-κB and COX-2-mediated pathway. World J Gastroenterol 11: 3197–3203.
46.
Yao, H., H. Wang, Z. Zhang, B.H. Jiang, J. Luo, X. Shi (2008) Sulforaphane inhibited expression of hypoxia-inducible factor-1α in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 123: 1255–1261.
47.
Yoshimatsu, K., D. Golijanin, P.B. Paty, R.A. Soslow, P.-J. Jakobsson, R.A. DeLellis, K. Subbaramaiah, A.J. Dannenberg (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7: 3971–3976.
48.
Yoshitake, N., H. Fukui, H. Yamagishi, A. Sekikawa, S. Fujii, S. Tomita, K. Ichikawa, J. Imura, H. Hiraishi, T. Fujimori (2008) Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 98: 1682–1689.
49.
Zhou, J., D.G. Joplin, J.V. Cross, D.J. Templeton (2012) Sulforaphane inhibits prostaglandin E2 synthesis by suppressing microsomal prostaglandin E synthase 1. PLoS One 7: e49744.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.